Everest Group EG
Financial Services · Insurance - Reinsurance · Synthos Deep Dive · 2026-07-03
The Overview
Everest is a reinsurance company — it sells insurance to other insurance companies, plus some specialty commercial insurance. When a hurricane or earthquake hits, Everest helps pay the bill; in calm years it keeps the premiums as profit. It is based in Bermuda, it is large ($14.7B), old (founded 1973), and financially very solid (top A+ rating, little debt).
Is the stock cheap or expensive? Cheap. You pay about $7.60 for every $1 of last year's profit (most stocks cost far more), and the whole company trades at roughly the value of its own net worth (book value). Cheap for a reason, though: profits jump around wildly depending on how bad the disaster year is. In 2024 the company had to admit past claims cost more than expected and took a big loss; in early 2026 it bounced back to a strong profit.
Our verdict is Watch — a "keep an eye on it" call, not a "buy now." It's a fine, well-run, cheap business, but it does not grow much over time, and the Wall Street price targets actually sit below today's price.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (below average risk). Cheap and lightly indebted, so limited air underneath — but one bad catastrophe season can wipe out a year of profit.
- Growth Quality 4/10 (mediocre). It earns a decent ~13% return, but sales aren't really growing; management is deliberately shrinking the riskier lines.
- Exponential Potential 2/10 (low). This is a mature, up-and-down cyclical. Don't expect it to multiply — expect it to pay a dividend and grind.
The one big worry: a severe disaster year (major hurricanes or a quake) on top of another "we under-reserved" surprise like 2024 — that combination is what actually breaks a reinsurer.
Putting a number on it: our fair-value estimate is $390 against a current price of $377.61 — real upside if our numbers are right.
Our summary metrics
Cheap (7.6× EPS, 0.98× book) & low-levered (net-debt/EBITDA 0.85×, beta 0.31) — but catastrophe tail & 2024 reserve blowup keep it mid.
Reinsurance cycle, not secular growth — analysts model revenue FLAT-to-down and EPS lumpy; 13% ROE, no moat compounding.
Mature, cyclical Bermuda reinsurer; premiums shrinking as management shrinks-to-quality. No acceleration, no TAM story.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature, cyclical Bermuda reinsurer; premiums shrinking as management shrinks-to-quality. No acceleration, no TAM story.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $357 (high $377 / low $332; 8 Buy · 14 Hold · 0 Sell → Hold) — context; note it sits BELOW today's price |
| Valuation | 7.6× trailing EPS · ~7× FY26E · ~6× FY27E · 0.98× book · EV/EBITDA 6.6× · 2.2% dividend |
| Technicals | At the 52-wk high ($371), above 50/200-DMA, but RSI 82 = overbought; +8.9% 12-mo lagged SPY +20.6% |
| Conviction | Low — 0 expert voices, 0 claims in the KB; the call rests entirely on fundamentals and quant |
| Position sizing | If owned: small ~1–3% value/ballast sleeve, not a core growth holding |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for EG — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $377.61, 2% above the 50-day average ($370), 11% above the 200-day average ($341) — an uptrend. 5% below the 52-week high of $399, 24% above the 52-week low of $305.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $377.61 is currently inside the band (band $361–$380).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 56.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.83, positive momentum.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = EG · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Everest Group, Ltd. (NYSE: EG) is a Bermuda-domiciled global reinsurance and insurance underwriter, founded 1973, IPO 1995, renamed from Everest Re Group to Everest Group in July 2023. It writes property, casualty, and specialty reinsurance (treaty and facultative — mortgage, catastrophe, marine, aviation, credit/surety, motor, agriculture, etc.) sold to ceding insurers, plus commercial insurance through wholesale/retail brokers and program administrators. ~3,000 employees. CEO Jim Williamson. Fiscal year ends December 31.
Revenue mix (segments). FMP's product segmentation is stale — it still shows the old two-segment structure (FY2024: Reinsurance $11.4B · Insurance $3.6B · Other $0.2B). As of Q1'26 management has re-cut the business into three reportable segments (per the SEC 8-K earnings release, §9): Reinsurance Treaty, Global Wholesale Specialty, and Legacy (run-off). In Q1'26, Reinsurance Treaty drove essentially all underwriting income ($315M of $316M group pre-tax underwriting income); Global Wholesale Specialty added $23M; Legacy was a −$22M drag. Geographic segmentation was not provided by FMP (seg_geo empty).
The strategic story in one line: "shrink to quality." Group gross written premium fell 18.5% year-over-year in Q1'26 as management deliberately walked away from underpriced casualty and non-cat property, defending the combined ratio rather than chasing top line.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage for EG in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. No investor, analyst, or operator in our tracked panel has said anything about Everest that we can reconcile to a real claim_id.
Per house standard, we do not fabricate conviction. This verdict is therefore entirely fundamentals- and quant-driven: it rests on the reported financials (FMP), the analyst consensus estimates (FMP), management's own SEC 8-K guidance (half-weighted, §9), and the Synthos scoring framework. Treat the absence of KB breadth as a genuine limitation — where LLY carries 13 net-bullish voices and 251 claims, EG carries zero, which is one reason its conviction rating is Low and its verdict is a cautious Watch rather than a Buy.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Below-average | Cheap (7.6× EPS, 0.98× book), lightly levered (net-debt/EBITDA 0.85×), low beta 0.31, A+ rated — but a catastrophe-exposed cyclical with a fresh memory of the 2024 reserve blowup (Q4'24 net loss −$593M). Valuation floor offsets tail risk → mid-low. |
| Growth Quality | 4 · Mediocre | ROE ~13% TTM is fine, not elite; ROIC ~10%. But revenue is flat-to-down on consensus, GWP is shrinking 18% YoY by design, and earnings are lumpy (EPS $60→$32→$38 across FY23–25). No margin compounding, no moat that widens. |
| Exponential Potential | 2 · Low | Mature Bermuda reinsurer. Growth is cyclical, not secular (rate hardening/softening), the second derivative is negative (premiums contracting), and there is no TAM story or acceleration. A value/yield name, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities; the cases bound the range, and the scores above summarize them. Because reinsurers are valued on book value × ROE more than on an earnings multiple, we anchor primarily to price-to-book and cross-check on P/E.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Benign catastrophe year; the "shrink-to-quality" reset holds combined ratio in the low-90s; ROE sustains ~16–17%; market re-rates toward ~1.2× book on ~$400+ BVPS. FY27E EPS ~$60 at ~8×. | ~$500 (+35%) |
| Base (our anchor) | Normalized catastrophe load; combined ratio mid-90s; ROE ~13–14%; the stock earns roughly ~1.0× book (BVPS ~$390, growing) with EPS ~$52–60 at ~6.5–7×. | ~$390 (+5%) |
| Bear | Heavy catastrophe year and/or another adverse reserve charge like 2024; ROE dips to high-single-digits; multiple de-rates to ~0.7× book. EPS compresses toward ~$30. | ~$270 (−27%) |
Synthos fair value = the base case, ~$390 (+5%), with the full $270–$500 span as the honest range. This anchor sits modestly above the Street's $357 consensus (which itself is below today's $371 price — the Street sees EG as fully-to-slightly-over valued after its run to the 52-week high). The thin upside to base and the below-price Street target are exactly why this is a Watch, not a Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). EG is neither — it is a mature cyclical:
- Forward growth: consensus models revenue falling from FY25 $17.3B toward ~$15.6–16.1B (FY26E–FY28E) and EPS recovering off the depressed FY24/FY25 base to ~$52 (FY26E) → ~$60 (FY27E) → ~$70 (FY28E). The EPS "growth" is a cyclical rebound, not secular expansion.
- Acceleration (the 2nd derivative) is negative on the top line: gross written premium is contracting 18.5% YoY by management's own choice (shrink-to-quality). There is no demand inflection to ride.
- Room to run: reinsurance is a mature, competitive, capital-cyclical market. There is no large-and-growing TAM the way there is in software or GLP-1 drugs; pricing power ebbs and flows with the underwriting cycle and catastrophe experience.
- Reinvestment runway: capital is returned (buybacks $331M in Q1'26, ~$818M FY25; 2.2% dividend) rather than reinvested into a compounding flywheel — the correct choice for a mature underwriter, but the opposite of an exponential.
Exponential Potential: Low (2/10). Own EG, if at all, for cheap book value, a ~13% ROE, and capital return — never for a fast multibagger. This honest framing places EG in a value/ballast sleeve, not the growth or "next-exponential" flagship.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $17.32B (+1.4% on FY24 $17.08B; FY23 was $14.46B). Total revenue includes premiums earned + net investment income; the top line is roughly flat and consensus sees it drifting down as premiums shrink.
- Earnings — lumpy by nature: net income $1.59B FY25 (EPS $37.86) vs $1.37B FY24 (EPS $31.78) vs $2.52B FY23 (EPS $60.19). The swing is catastrophe/reserve-driven, not operational drift.
- The 2024 scar: Q4'24 was a net loss of −$593M (EPS −$13.77) on a large casualty reserve strengthening — the single most important risk tell in the file. It is why FY24 EPS collapsed and why "are reserves adequate?" is the central question on this name.
- The 2026 rebound: Q1'26 net income $653M, EPS $16.21 (vs $210M / $4.90 a year earlier), combined ratio 91.2% (from 102.7%), catastrophe losses just $130M (vs $472M), and a 16.7% operating ROE. Net investment income rose to $567M on strong alternatives.
- Margins / returns: net margin ~11.9% TTM, ROE 13.3% TTM, ROIC ~10.4%. Decent, cyclical, not elite.
- Cash flow: operating cash flow $3.40B FY25 (reinsurers run high OCF as premiums are collected ahead of claims); FCF ≈ OCF (negligible capex). Investment portfolio ~$44B is the real engine.
- Balance sheet: total debt $3.59B, cash & ST investments $19.5B, net debt $2.27B, net-debt/EBITDA 0.85×, book value ~$379/share (P/B 0.98×). A+ letter rating (overall score 4/5). Financially sturdy.
6. Valuation — priced in or room?
On headline multiples EG is cheap: 7.6× trailing EPS, ~7× FY26E, ~6× FY27E, 0.98× book, EV/EBITDA 6.6×, 2.2% dividend, ~19% FCF yield. But "cheap" is the normal state for a catastrophe-exposed cyclical — the market rationally refuses to pay a high multiple on earnings that can swing to a loss in a bad year (see Q4'24). The right lens for a reinsurer is price-to-book against ROE: at ~1.0× book earning ~13–17% ROE, EG is fairly valued, arguably slightly cheap if the low-90s combined ratio proves durable, and expensive if 2024-style reserve risk recurs.
Street targets (context, not our anchor): consensus $357, high $377, low $332 — notably below the current $371 price, with a Hold rating (8 Buy / 14 Hold / 0 Sell). The Street effectively says "fully valued after the run to highs." Our base FV of ~$390 is a touch more constructive (we give some credit to the operating-ROE reset and growing book value) but still implies only ~+5% — thin. The FMP letter grade is A+, reflecting quality (low debt, good ROE, cheap multiple), which is not the same as upside. Not a bargain with a catalyst; a cheap-but-going-nowhere cyclical — hence Watch.
7. Technicals (from the tech block / quote)
- Trend: up but extended. $371.35 sits above the 50-DMA ($344.8) and 200-DMA ($334.6), 50 above 200 (golden-cross posture), MACD +6.0 (positive).
- Location: at the 52-week high ($371), +21.8% off the 52-week low ($305); max drawdown from peak just −10.4%. A name pressing new highs.
- Momentum — the caution flag: RSI(14) 82 = clearly overbought (>70). Chasing here is a poor entry; the technicals argue for waiting for a pullback toward the ~$345 50-DMA.
- Relative strength: EG +8.9% 12-mo vs SPY +20.6% (and QQQ +30.3%); +14.7% 3-mo roughly matched SPY +13.7%. A market laggard over 12 months that has caught up recently — momentum is fresh, not entrenched.
- Read: trend is constructive but overbought at a Street target it has already exceeded — no urgency to buy, and the RSI says don't chase.
8. Moat & competitive position
Reinsurance has a weak-to-modest moat: the "product" (capacity) is largely fungible capital, pricing is cyclical, and returns mean-revert. Everest's edges are real but not wide — scale ($44B investment portfolio, global platform), an A+ balance-sheet/rating that lets it write large treaties, underwriting discipline (the shrink-to-quality reset), and a growing specialty/wholesale book. But it competes head-to-head with better-diversified or higher-return peers and is a price-taker in soft markets. The 2024 reserve charge showed the moat does not protect against mis-estimating long-tail casualty risk.
Peer set (market cap, from FMP): RenaissanceRe (RNR) $13.9B — the closest pure-cat-reinsurance comp; Reinsurance Group of America (RGA) $14.5B; Brookfield Wealth Solutions (BNT) $14.4B; MetLife (MET) $57.9B; CNA Financial (CNA) $13.8B; Equitable (EQH) $12.4B; Fidelity National Financial (FNF) $13.1B; Erie Indemnity (ERIE) $12.0B; Banco de Chile (BCH) $19.9B. Against RNR and RGA, EG is mid-pack on ROE and trades at a comparable low book multiple — no valuation dislocation to exploit.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly — $331M of buybacks in Q1'26 (accelerated) plus ~$818M repurchased in FY25 and a 2.2% dividend ($8.00/share TTM, ~16% payout). Buying back stock at ~1× book is accretive to book value per share. Net-debt/EBITDA 0.85× leaves ample balance-sheet room.
- Insider activity: the sampled window (2026-04 to 2026-07) is dominated by routine director stock awards (86-share grants at $360.78) and CFO Elias Habayeb's onboarding equity — one small officer sale (Jason Keen, 775 shares). No alarming cluster of discretionary selling. Normal.
- Management's own guidance (half-weighted — their self-interested words): the SEC 8-K (Item 2.02) earnings release for Q1'26 (filed 2026-04-29) is a genuine earnings release. CEO Jim Williamson: "Everest delivered a strong start to the year as the strategy we implemented to improve our return profile and capital efficiency is becoming evident… Solid contributions from underwriting and investment income drove an annualized operating ROE of 16.7% and supported accelerated share repurchases." Forward framing: "As we look forward through 2026, we are focused on executing against our strategy, centered around underwriting discipline and accelerating capital return." Management does not give hard revenue/EPS guidance (typical for reinsurers) — it guides to process (discipline, capital return), not numbers. Weight this as management's own book; the numbers to trust are the combined ratio (91.2%) and ROE (16.7%) they actually reported.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $14.25, revenue ~$4.0B). Watch the combined ratio and any prior-year reserve development line (favorable vs adverse) above all.
- Atlantic hurricane season (Jun–Nov): the single biggest swing factor for a property-cat reinsurer's full-year result. A quiet season is the bull case; a Katrina/Ian-scale event is the bear case.
- January & mid-year reinsurance renewals: pricing (rate) and how much premium management chooses to write vs walk away from — the shrink-to-quality reset in action.
- Reserve adequacy: any further casualty reserve strengthening would re-open the 2024 wound and hit the stock hard; continued favorable development (as in Q1'26, +$33M) confirms the reset.
- Net investment income: ~$44B portfolio; sustained alternatives/rate income is a quiet earnings support.
Thesis tripwires (what would change the call): a fresh adverse reserve charge; combined ratio back above 100%; ROE falling into the high-single-digits; or a de-rating below ~0.8× book on a bad-cat year. Conversely, two-plus quarters of low-90s combined ratio and 15%+ ROE with growing book value would upgrade the case toward Buy — Tactical.
11. Key risks
- Catastrophe tail (structural, cyclical): a severe hurricane/earthquake year can turn a profit into a loss; property-cat is the core exposure. Non-diversifiable and lumpy.
- Reserve adequacy (the 2024 lesson): Q4'24's −$593M loss came from casualty reserve strengthening — the market's biggest fear is a repeat. Long-tail casualty is hard to estimate.
- Cyclical pricing / no secular growth: returns mean-revert with the underwriting cycle; premiums are currently shrinking. This is a value name with a flat-to-down top line, not a grower.
- Valuation offers little upside: Street target ($357) sits below the current price ($371); RSI 82 is overbought. Limited margin of safety on price even though the multiple is low.
- No expert coverage / low conviction: zero KB claims means the Synthos panel offers no independent corroboration — the entire call is model-and-data driven.
12. Verdict, position sizing & monitoring
Watch. Everest is a genuinely cheap (7.6× EPS, ~1× book), low-leverage, A+-rated global reinsurer that has executed a credible turnaround off the 2024 reserve shock — Q1'26's 91.2% combined ratio and 16.7% operating ROE are real, and capital return is aggressive. But it is a mature, catastrophe-exposed cyclical with shrinking premiums, no moat that compounds, no expert coverage in our KB, and a stock that has run to its 52-week high at an overbought RSI, above the Street's own price target. The honest read is fairly valued with thin upside and a fat tail — that is a Watch, not a Buy.
- Sizing: if owned, a small ~1–3% value/ballast position (reinsurance is a portfolio diversifier with low beta 0.31), not a core growth holding. No reason to chase at the 52-week high; a pullback toward the ~$345 50-DMA would be a better entry.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with special attention to reserve development and the combined ratio. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $371.35.
- Single biggest risk: a major-catastrophe year compounded by another adverse reserve charge like 2024.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — Everest has no expert coverage in the Synthos knowledge base, so this note carries no inline
claim_idcitations and the verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and none is asserted here. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 (live FMP). Forward figures are analyst consensus (FMP), labeled as estimates. Note FMP's product segmentation is stale (old two-segment structure); the current three-segment structure is taken from the SEC 8-K.
- Management caveat: the Q1'26 SEC 8-K (Item 2.02) guidance is management's own book, half-weighted by design; management guides to process (underwriting discipline, capital return), not hard revenue/EPS numbers.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").